The historical rank and industry rank for Thyrocare Technologies's FCF Margin % or its related term are showing as below:
NSE:THYROCARE'
s FCF Margin % Range Over the Past 10 Years
Min: 13 Med: 18.05 Max: 36.96
Current: 23.2
During the past 13 years, the highest FCF Margin % of Thyrocare Technologies was 36.96%. The lowest was 13.00%. And the median was 18.05%.
NSE:THYROCARE's FCF Margin % is ranked better than 92.61% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.89
vs NSE:THYROCARE: 23.20
Thyrocare Technologies FCF Margin % Related Terms
Thyrocare Technologies FCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:THYROCARE vs TMO, DHR, IDXX: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Thyrocare Technologies's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thyrocare Technologies FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Thyrocare Technologies's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thyrocare Technologies (NSE:THYROCARE) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Thyrocare Technologies and its competitors. Over the past decade, Thyrocare Technologies' FCF Margin % has ranged from 13.00 to 36.96. According to the industry distribution chart, Thyrocare Technologies ranks #15 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 7.4%.
Is Thyrocare Technologies' FCF Margin % too high?
Thyrocare Technologies' current FCF Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 13.00 to a high of 36.96. Based on the distribution chart, Thyrocare Technologies ranks #15 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Thyrocare Technologies has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Thyrocare Technologies ranks #15 out of 203 companies for FCF Margin %. This places Thyrocare Technologies in the top 7% of its industry — outperforming the majority of peers. Historically, Thyrocare Technologies' own FCF Margin % has ranged from 13.00 to 36.96 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Thyrocare Technologies and its competitors. Thyrocare Technologies's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹391.69, compared to a current price of ₹524.40 — trading 33.9% above its estimated fair value. The current FCF Margin % is 0.00%. Thyrocare Technologies' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?
Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued.
The current stock price of ₹524.40 is trading 33.9% above its estimated GF Value™ of ₹391.69.
GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.
Key valuation signals for NSE:THYROCARE:
FCF Margin %: 0.00%
GF Value™: ₹391.69 vs. price of ₹524.40 (33.9% above fair value)
No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
87GF Score
Get the complete analysis for NSE:THYROCARE
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THYROCARE has been successfully added to your 
